Diabetes Australia welcomes the Federal Authorities’s resolution to ban replicas of Ozempic and different weight reduction drugs following security considerations.
Pharmacies compounding their very own variations of those drugs have been ordered to cease manufacturing from October 1, 2024.
The brand new rules will take away glucagon-like peptide-1 receptor agonists (GLP-1RAs), a lot of which declare to be replicas of Ozempic or Mounjaro, from the pharmacy compounding exemption.
Diabetes Australia understands the numerous considerations of Australians residing with sort 2 diabetes concerning the ongoing world scarcity of Ozempic specifically, and can proceed to advocate for prioritised entry for folks residing with diabetes.
Nonetheless, in relation to compounded variations, the well being and wellbeing of the group should be crucial consideration.
The compounded GLP-1RA merchandise the federal government has banned haven’t been evaluated by the TGA for security, high quality and efficacy. When a drugs is compounded, it might have a distinct power and totally different substances from related medicines accredited by the TGA.
Diabetes Australia has advocated for the Therapeutic Items Administration (TGA) to analyze the shortages of quite a few diabetes-related medicines and merchandise in recent times and redouble efforts to make sure Australians will be assured that provide chains are enough to fulfill their wants.
Extra details about the protection of those merchandise will be discovered on the TGA web site.
